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Abstract
Objective To investigate the association between exposure to antibiotics in fetal and early life and asthma in
childhood, with adjustment for confounding factors.
Design Nationwide prospective population based cohort study, including sibling control design.
Setting Swedish population identified from national demographic and health registers.
Participants 493 785 children born 2006-10; 180 894 of these were eligible for sibling analyses.
Main outcome measure Asthma defined as having both an asthma diagnosis and dispensed asthma drugs.
The association between antibiotic exposure and asthma was investigated in the whole cohort with Cox
proportional hazard regression. A stratified proportional hazards model conditional on sibling group was
used to adjust for shared factors within families. Confounding by respiratory infections was assessed by
investigating whether specific groups of antibiotics were associated with asthma.
Results Antibiotic exposure in fetal life was associated with an increased risk of asthma in cohort analyses
(hazard ratio 1.28, 95% confidence interval 1.25 to 1.32), but not in sibling analyses (0.99, 0.92 to 1.07). In
cohort analyses, antibiotics used to treat respiratory infections in childhood were associated with a more
pronounced increased risk of asthma (4.12, 3.78 to 4.50) than antibiotics used for urinary tract and skin
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infections (1.54, 1.24 to 1.92). In sibling analyses, the excess risks after exposure to antibiotics for
respiratory infections decreased (2.36, 1.78 to 3.13) and disappeared for antibiotics for urinary tract and skin
(0.85, 0.47 to 1.55).
Conclusions Previous positive associations between exposure to antibiotics in fetal and early life and
subsequent childhood asthma could have been caused by confounding by shared familial factors, in addition
to confounding by respiratory infections.
Introduction
The increasing use of antibiotics has coincided with a rise in childhood asthma.   This has triggered a surge
of observational studies investigating the potential harmful role of exposure to antibiotics in fetal life    
 and childhood                on subsequent development of wheeze and asthma.
Earlier results, however, are conflicting, possibly because of different selection of populations, study
designs, and potential bias. Previous studies that have found positive associations between antibiotic
exposure in fetal life and childhood asthma have hypothesised that treatment of the mother with antibiotics
during pregnancy could trigger a disease process in perinatal life in susceptible individuals.    Some
studies have also suggested that a causal association between antibiotic exposure in childhood and asthma is
plausible    and, in line with the microflora hypothesis, that exposure to antibiotics could lead to an
increased incidence of allergic disease such as asthma.
Systematic reviews have highlighted that the associations between antibiotic exposure and asthma could be
caused by bias.   Confounding by indication implies that the association is confounded by a third factor
(such as respiratory infections) that could be the indication for antibiotic use and a risk factor for asthma,
whereas reverse causation indicates that first occurrences of symptoms of asthma (associated with
respiratory infections) have been treated with antibiotics, thereby inducing an association between
antibiotics and asthma. Lack of adjustment for residual familial factors—for example, genetic and
environmental confounding factors shared within families such as a genetic predisposition to respiratory
infections and asthma, consultation patterns or other lifestyle and home environmental factors—is another
potential source for bias.   Some studies have suggested that the association between antibiotics and
asthma might be confounded by indication or reverse causation       or consultation patterns.  
 To date, however, no study has investigated the association between exposure to antibiotics measured
from the start of pregnancy and childhood asthma, taking familial factors into account.
Sibling studies provide the opportunity to study the association between antibiotics and asthma, with
adjustment for familial factors.  Full siblings share half of their genes, some intrauterine exposures, and
parental factors and can be discordant regarding exposure to antibiotics. If associations seen in a cohort of
siblings remain when non-affected siblings are used as controls for the affected children, then factors
specific to each individual (such as the indication for antibiotic treatment) are assumed to be involved in the
underlying causal pathways. On the contrary, if the association disappears or is diluted, it indicates that
factors common to the siblings (such as parental factors) are involved.
We examined the association between exposure to antibiotics in fetal life or childhood and subsequent
development of asthma by examining a prospective nationwide cohort of children followed from start of
their mother’s pregnancy up to school age. By exploring the association within families using sibling
controls, we adjusted for familial factors, thereby further assessing causality. We studied the possibility of
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Exposure
Outcome
Other variables
confounding by indication and reverse causation from respiratory infections by investigating whether
specific groups of antibiotics (as a proxy for the indication of the treatment) were associated with asthma.
Method
Study population and design
This nationwide population based register study included Swedish children born to women who were
pregnant between July 2005 and December 2010, identified from the Medical Birth Register. The cohort
was linked to the Multi-Generation Register with the Swedish personal identity number to identify parents
and siblings. The personal identity number enables unambiguous linkage between the registers held by the
Swedish National Board of Health and Welfare and Statistics Sweden.
Variables
We collected information on exposure and outcome from the Swedish Prescribed Drug Register, which
contains complete data on dispensed drugs since July 2005, and the National Patient Register with complete
nationwide information on all inpatient diagnoses since 1987 and specialist outpatient diagnoses since 2001.
Information on generic names and dates of filled prescriptions of systemic antibiotics
(Anatomical Therapeutic Chemical (ATC) classifications system code J01A-J01X) was retrieved from the
Swedish Prescribed Drug Register from July 2005 to the end of follow-up. All antibiotics were divided into
three groups, modified from Marra and colleagues  and as described elsewhere  : “any antibiotics”
included any type of antibiotics; “airway antibiotics” included antibiotics used to treat respiratory infections
(amoxicillin, penicillin, cephalosporin, and macrolides), and “urinary tract or skin and soft tissue
antibiotics” (pivmecillinam, trimethoprim, sulphonamide, ciprofloxacin, norfloxacin, nitrofurantoin,
cloxacillin, flucloxacillin, and dicloxacillin).
Children were classed as having asthma if they had a diagnosis of asthma (ICD-10 (international
classification of diseases, 10th revision) J45) registered in the National Patient Register and fulfilled one or
both of two criteria for asthma drugs (ATC: R03) from the Swedish Prescribed Drug Register: two or more
dispensed inhaled corticosteroids, leukotriene receptor antagonists, or fixed combinations of β2 agonists and
corticosteroids, with gaps of two or more weeks between distributions or three or more dispensed asthma
drugs as previously mentioned or short acting β2 agonists within a year.  Date of onset was set as the date
of prescription of any of the drugs or date of diagnosis, whichever came first.
We collected information on child’s birth year, sex, birth weight (grams), gestational age
(days), mode of delivery (vaginal, instrumental, emergency, or elective caesarean section), maternal
smoking at first visit to the antenatal care clinic (yes/no), respiratory diagnosis as newborn (ICD-10: P22-
P28), maternal age at delivery, parity (child’s birth order), family situation (mother cohabits with child’s
father, or other), mother’s country of birth (Sweden, other Nordic countries, or other) from the Medical
Birth Register, which includes data on more than 98% of all births in Sweden. The highest level of
education of either parent (0-9, 10-12, >12 years) was retrieved from the Longitudinal integration database
for health insurance and labour market studies. Maternal asthma was defined as the mother having either
fulfilled the criteria of dispensed asthma drugs or a diagnosis of asthma during the study period.
Start date of pregnancy was estimated as the date of birth minus gestational age in days. Duration of
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Sensitivity analyses
pregnancy was further divided into three trimesters (first: 1-91 days; second: 92-189 days; third: ≥190 days).
To ensure full coverage of exposure to antibiotics during fetal life and childhood from the Swedish
Prescribed Drug Register, we restricted the cohort to children from pregnancies with an estimated start date
of pregnancy as on or after 1 July 2005. Information on date of migration and death was collected from the
Total Population Register. We excluded 9631 children born to women who migrated to Sweden during the
pregnancy.
Statistical analysis
The analyses were performed in two steps. Firstly, we analysed the association between antibiotic exposure
and asthma in the whole cohort of children using Cox proportional hazard regression, with attained age as
analysis time scale and sandwich estimator of standard errors to account for clustering within sibling groups.
Follow-up was censored at study outcome, emigration, death, or end of study period (31 December 2011),
whichever occurred first. Exposure to antibiotics in childhood was included in the model as a time (age)
varying exposure. The proportional hazards assumption was tested with Schoenfeld’s residuals. Non-
proportional hazards were found for childhood exposure to antibiotics. Consequently, we allowed for time
varying effects.
Secondly, we used a sibling control design to adjust for familial factors. For the controls we used all full
siblings (excluding 9896 children for whom the father’s identity was unknown) who did not have the
outcome of interest yet and who were still in the study at the at which the index child developed asthma.
While all siblings with discordant outcomes contribute to the hazard ratio estimates of the covariates, only
siblings who are also discordant on exposure are informative for the estimation of the hazard ratios for the
exposure. Thus, for tabulated frequencies in the sibling control analyses we report the number of families
with siblings discordant on both outcome and exposure. There were one to four controls per case and cases
without eligible sibling controls were excluded. We used a stratified Cox proportional hazard model
conditional on sibling group to analyse the sibling control design data.
Results are reported both as crude and adjusted for maternal smoking during pregnancy, parity, family
situation (cohort and sibling analyses), mother’s country of birth, parental education, and maternal asthma
(only cohort) for the analyses of antibiotic exposure in fetal life. Analyses of exposure to antibiotics in
childhood were adjusted for child’s sex, birth weight, gestational age, mode of delivery, respiratory
diagnosis as newborn, maternal age at delivery, parity, family situation, maternal antibiotic exposure in fetal
life (cohort and sibling analyses), and mother’s country of birth, parental education (only cohort) and for
interaction between age and parity (only sibling analyses).
We performed subanalyses to explore the association of exposure during first, second, and third trimester of
the pregnancy and asthma, and between exposure to antibiotics in the first year of life and incident asthma
from the age of 2.
A Poisson regression model, with restricted cubic splines (six knots) for time since first antibiotic exposure,
was fitted to further assess potential reverse causation.
The Swedish Prescribed Drug Register reports only on antibiotics dispensed outside
hospitals and most of antibiotics in Sweden (90%) are captured in the register.  In a sensitivity analysis,
however, we included in the group “any antibiotics” those children who had been admitted to hospital and
given a diagnosis previously shown to have a high correlation with antibiotic treatment.  The effect of
antibiotic exposure on asthma in the full cohort was further investigated by inclusion of interaction terms
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between birth order (first born compared with not first born) and antibiotic exposure. The association
between antibiotics in childhood and asthma was further tested for a dose-response relation between number
of prescriptions (0, 1, 2-3, or ≥4 as a continuous variable) and asthma. All analyses of exposure to
antibiotics in fetal life and childhood and subsequent asthma were also analysed with asthma drug and
diagnosis separately and further restricted to mothers born in Sweden.
All analyses were performed with Stata statistical software, version 13.
Results
Figure 1 shows the final study populations for the cohort and sibling control analyses. We included 493 785
children in the cohort analyses, and 180 894 were eligible for the sibling control analyses. During the study
period 4922 children emigrated and 1448 died. Tables 1 and 2 show the prevalence of asthma by cohort
characteristics for the full cohort and for the sibling cohort . Overall, 6% of the children in the cohorts were
defined as having asthma. In total, 20% of the children in the full cohort and 16% of the children in the
sibling cohort had been exposed to antibiotics in fetal life, and at least one prescription of any antibiotic
during childhood was filled for 62% of children in both cohorts. An additional 4% of children in both
cohorts were assumed to have been exposed to antibiotics in hospital.
Antibiotics in fetal life
Table 3 shows the crude and adjusted hazard ratios and 95% confidence intervals for the association
between antibiotics in fetal life and childhood asthma in the cohort and sibling control analyses. The crude
cohort analyses showed that any antibiotics in fetal life was significantly associated with a 36% increased
risk of asthma in childhood. There was a comparable increased risk for airway antibiotics (hazard ratio 1.41,
95% confidence interval 1.37 to 1.46). The excess risk associated with urinary tract/skin antibiotics was
somewhat lower, but still significantly associated with asthma (1.25, 1.20 to 1.30). After adjustment for
confounding variables, antibiotic exposure in fetal life remained significantly associated with asthma but
reduced for any and airway antibiotics. In the sibling control analyses, the association disappeared; the
adjusted hazard ratio was 0.98 (0.90 to 1.07) for airway antibiotics and 0.98 (0.88 to 1.10) for urinary
tract/skin antibiotics. We found no difference in the hazard ratios (cohort and sibling control analyses)
between trimesters for any group of antibiotics.
Antibiotics during childhood
Tables 4 and 5 show the crude and adjusted hazard ratios and 95% confidence interval for asthma in relation
to any antibiotics in different age bands in the full cohort and sibling control analyses . The highest risk was
found among the youngest children (adjusted hazard ratio 3.71, 95% confidence interval 3.41 to 4.03), and
risk decreased with age (table 4). In the sibling control analyses all estimates were clearly lower than in the
cohort analyses (2.11, 1.61 to 2.76, in the youngest children) (table 5). We found similar estimates in
sensitivity analyses including children with presumed antibiotic exposure in hospitals in the group any
antibiotics.
Table 6 and 7 show the associations between airway and urinary tract/skin antibiotics and subsequent
asthma . For both groups of antibiotics, the cohort analyses showed a decreased hazard ratio with increasing
age, but the difference in risk was more pronounced after exposure to airway antibiotics (adjusted hazard
ratio 4.12, 95% confidence interval 3.78 to 4.50) compared with urinary tract/skin antibiotics (1.54, 1.24 to
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1.92) in the youngest children (table 6). In the sibling control analyses, the estimates were clearly decreased
compared with the cohort analyses, where the association with airway antibiotics remained significant (2.36,
1.78 to 3.13), and the association between urinary tract/skin antibiotics and asthma disappeared (0.85, 0.47
to 1.55) (table 7).
Table 8 and 9 shows the associations between antibiotic exposure in first year of life and incidence of
asthma from the age of 2 . We found significant associations for all groups of antibiotics with asthma in the
cohort analyses, but no associations remained in the sibling control analyses.
Figure 2 shows the hazard ratio for asthma in relation to time since first exposure to any, airway, and
urinary tract/skin antibiotics in childhood. The hazard ratio for asthma in relation to any and airway
antibiotics decreased steeply with time since exposure from about four to two during the first six months
after antibiotic treatment. For urinary tract/skin antibiotics the hazard ratio slightly increased after exposure
and then returned to the initial hazard ratio of around 1.25 in the years after exposure.
Sensitivity analyses showed that first born children had a higher excess risk of asthma than subsequent
children after exposure to any and airway antibiotics before 1.5 years of age (P<0.001 for interaction
between birth order and exposure) but not after exposure to urinary tract/skin antibiotics (P=0.38). In the full
cohort, we found a dose-response relation for the association between increasing number of prescriptions for
all groups of antibiotics and asthma (P<0.001, all age groups). In sibling analyses, the dose-response
relation remained for any and airway antibiotics (P<0.001, all age groups), but not for urinary tract/skin
antibiotics (P=0.22-0.97 for different age groups). Analyses restricted to mothers born in Sweden produced
similar estimates (data not tabulated). Analyses repeated with asthma drugs and diagnosis as separate
outcomes yielded comparable estimates (tables A-C in appendix).
Discussion
Our results, based on a nationwide population based birth cohort, show a positive association between
exposure to antibiotics in fetal life or childhood and subsequent asthma. In sibling control analyses,
however, these associations disappeared or clearly decreased, indicating that the association might be
strongly confounded by factors shared by families. To our knowledge, this is the first study to use sibling
control analyses to assess the causality of the association between antibiotics and asthma. Our findings
support the view that the association between fetal exposure to antibiotics and asthma is affected by
confounding factors shared by siblings. We also found that the association between antibiotics for urinary
tract/skin conditions in childhood and asthma disappeared in the sibling analyses. In analyses restricted to
exposure during the first year of life and incident asthma from the age of 2, the association disappeared for
all groups of antibiotics. This indicates that the association seen in the cohort is confounded both by familial
factors and by indication or reverse causation.
Previous studies
Some previous studies have suggested that exposure to antibiotics in fetal life increases the risk of
subsequent asthma and wheeze,    whereas another study, with a fairly small study population, reported
similar estimates but no significant associations.  It has also been reported that the risk of transient early,
persistent, and late onset wheezing differed by types of antibiotics, though exposure during pregnancy and
wheezing outcomes were based on parental report and thus recall bias might have been a problem.  In
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accordance with others we found similar risks of asthma regardless of trimester  and groups of antibiotics,
 and the risk disappeared altogether in the sibling analyses.
Our results from the cohort analyses suggest that the excess risk of asthma after exposure to antibiotics in
childhood decreases with increasing age.    In addition, the excess risk decreases with time since first
exposure to any and airway antibiotics independent of age at first exposure.  In line with the microflora
hypothesis,  which suggests that antibiotics can disrupt the normal microflora-mediated mechanisms of
immunological tolerance in the mucosa leading to an increased risk of allergic immune responses, it could
be hypothesised that the impact of antibiotics on the gut microflora and development of the immune system
is strongest in the first year of life or shortly after exposure.
Alternatively, our cohort results could be explained by difficulties in differentiating early wheezing caused
by respiratory infections from asthma or obstructive bronchitis in young children.  Consequently, first time
symptoms of asthma might be treated with antibiotics, thereby inducing an association between antibiotics
and asthma (reverse causation). Alternately, antibiotics were given to treat respiratory infection, in itself a
risk factor for asthma, resulting in confounding by indication. Adjustment for respiratory infections has
previously led to decreased risk estimates or loss of statistical significance, further supporting these
potential sources of bias.     We could not adjust for respiratory infections because the Swedish
Prescribed Drug Register does not provide indication for the actual prescriptions, nor were we able to adjust
for number of doctor’s visits as visits in primary care are not recorded in the National Patient Register. Yet,
based on previous studies   and standardised treatment guidelines, we categorised antibiotics into those
used to treat respiratory infections or not, and we confirm previous findings that airway antibiotics were
associated with asthma, whereas urinary tract/skin antibiotics were not.  Metsälä and colleagues recently
found that the effect of urinary tract antibiotics on asthma, although not significant, was similar to the effect
of airway antibiotics.  Marra and colleagues found a significant risk of asthma independent of classes of
antibiotics and an increasing risk with number of antibiotic courses administered.  We also found an
increased risk of asthma   and a dose-response relation between number of prescriptions and asthma  for
any type of antibiotics in the cohort analyses. In the sibling analyses independent of timing of exposure,
however, the association and dose-response relation disappeared for urinary tract/skin antibiotics.
Furthermore, in sibling analyses restricted to exposure in first year of life, the associations disappeared for
all groups of antibiotics. The discrepancy between our studies could be caused by variances in antibiotic
prescription practices between countries or by our approach of adjusting for shared factors within families.
Having older siblings has been suggested to protect younger children from developing asthma.  We found
that firstborn children had a higher excess risk of asthma than subsequent children after exposure to any and
airway antibiotics before the age of 1.5 years. There was no difference after exposure to urinary tract/skin
antibiotics. These results support that the associations seen in the cohort, independent of birth order, are
confounded by familial factors and by indication or reverse causation. In a study by Semic-Jusufagic and
colleagues, the possibility of confounding by indication was further highlighted.  The authors found that
antibiotics given in early life were associated with an increased susceptibility to viral infections because of
impaired antiviral immunity and also to genetic variants on chromosome 17q21 locus, which is strongly
associated with asthma.
In the sibling control analyses we were able to adjust for residual genetic and environmental confounding
factors shared by families, such as a genetic predisposition to respiratory viral infections and asthma,
consultation patterns, lifestyle, and home environmental factors. Thus, even though we confirmed previous
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positive associations between antibiotic exposure in fetal life and childhood and asthma in our cohort
analyses, the associations disappeared or clearly decreased in sibling control analyses, indicating that
previous studies as well as our own cohort results might be confounded by familial factors. The remaining
effect of airway antibiotics is most likely caused by confounding by indication or reverse causation, which
is not accounted for in the sibling analyses. This is further supported by the subanalyses restricted to
children exposed in first year of life and incident asthma from age 2, in whom the association disappeared
for all groups of antibiotics.
Strengths and limitations
The strength of our study is the large dataset in which full siblings have been identified, allowing for
analyses taking shared (unmeasured) factors within families into account. Furthermore, with objectively and
prospectively collected measures of exposure and validated outcomes  from population based registers,
precluding recall bias, we were able to assess the association between antibiotics and asthma over time. In
addition to information on prescribed antibiotics, we were also able to include information on assumed
exposure to antibiotics in hospital. Moreover, our population based design means our findings are
generalisable.
The study has some limitations. Firstly, we were not able to take adherence to treatment  or delayed
prescribing  into account. Yet, exposure to antibiotics was defined as a filled prescription for antibiotics,
which reduces the risk that delayed prescribing affected our results. Secondly, we were not able to control
for antibiotics prescribed abroad, which could be relevant for children of mothers born outside Sweden, who
might spend longer periods abroad, potentially leading to associations driven towards the null. Sensitivity
analyses restricted to children of women born in Sweden, however, produced similar results. Thirdly, even
with our large study population, the number of families discordant for both urinary tract/skin antibiotics in
childhood and asthma were fewer than in the analyses of fetal exposure, yielding broader confidence
intervals.
Conclusion and implications
In conclusion, our study suggests that the association between antibiotics and asthma is caused by
confounding factors shared within families, in addition to confounding by indication or reverse causation
because of respiratory infections. As there is a considerable threat from antibiotic resistance worldwide, it is
of great importance to acknowledge that though antibiotics might not cause asthma, careful consideration is
required as to whether respiratory symptoms should be treated with them.
What is already known on this topic
Numerous studies have reported conflicting results regarding the association between antibiotic
exposure in fetal life and early childhood and subsequent development of asthma
Bias from confounding by indication and reverse causation from respiratory infections could
explain previous positive associations
Lack of adjustment for residual genetic and environmental confounding factors shared by
families is another potential source for bias, which has not been assessed to date
What this study adds
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Cohort analyses showed an increased risk of asthma after antibiotic exposure in fetal life and
childhood
The risk for asthma was stronger after childhood exposure to antibiotics used to treat respiratory
infections than for those used for urinary tract and skin infections, implying confounding by
indication or reverse causation
In the sibling analyses, the association between antibiotic exposure in fetal life and asthma
disappeared, indicating that the association was affected by factors shared by siblings. For
antibiotic exposure in childhood, the association disappeared for antibiotics used for urinary
tract and skin infection and clearly decreased for antibiotics used for respiratory infections
Cohort results and previous findings have been confounded by genetic and environmental
factors shared by families in addition to cofounding by indication or reverse causation
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Fig 1 Final study populations for cohort and sibling control analyses. *Estimated first start of pregnancy 1 July 2005; first
child born on 8 January 2006. †93% of families had two children; 7% of families had three to five children; 12 364 were
twins and 267 were triplets. Registers at National Board of Health and Welfare: MBR=Medical Birth Register;
SPDR=Swedish Prescribed Drug Register; NPR=National Patient Register. Registers at Statistics Sweden: TPR=Total
Population Register; LISA=Longitudinal integration database for health insurance and labour market studies; MGR=Multi-
Generation Register
Table 1
 Characteristics of children in full cohort and sibling cohort in analysis of association between fetal and
childhood exposure to antibiotics and development of asthma
Full cohort Sibling cohort
No of
children
No (%) with
asthma
No of
children
No (%) with
asthma
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Total No of children 493 785 29 753 (6.0) 180 894 11 260 (6.2)
Birth year:
 2006 73 865 5795 (7.9) 30 434 2 241 (7.4)
 2007 101 323 7765 (7.7) 36 350 2 603 (7.2)
 2008 103 467 7278 (7.0) 36 184 2 495 (6.9)
 2009 104 967 5930 (5.7) 35 553 2 337 (6.6)
 2010 110 163 2985 (2.7) 42 373 1 584 (3.7)
Sex:
 Male 254 020 19 093 (7.5) 93 380 7 377 (7.9)
 Female 239 765 10 660 (4.5) 87 514 3 883 (4.4)
Birth weight (g):
 <2500 21 183 2374 (11.2) 10 262 1 134 (11.1)
 2500-2999 54 499 3659 (6.7) 20 940 1 501 (7.2)
 3000-3499 157 486 9021 (5.7) 55 717 3 379 (6.1)
 3500-3999 169 582 9393 (5.5) 61 023 3 374 (5.5)
 4000-4499 72 722 4113 (5.7) 26 370 1 470 (5.6)
 ≥4500 17 600 1130 (6.4) 6 314 386 (6.1)
 Missing 713 63 (8.8) 268 16 (6.0)
Gestational age at delivery (weeks):
 ≤34 12 546 1771 (14.1) 6 023 816 (13.6)
 35-36 17 356 1588 (9.2) 7 634 709 (9.3)
 37-38 96 821 6903 (7.1) 36 841 2 685 (7.3)
 39-40 248 414 13 546 (5.5) 90 414 4 975 (5.5)
 ≥41 118 648 5945 (5.0) 39 982 2 075 (5.2)
Respiratory diagnosis at birth*:
 No 480 799 28 382 (5.9) 175 955 10 706 (6.1)
 Yes 12 986 1371 (10.6) 4 939 554 (11.2)
Antibiotic exposure in fetal life†:
 Any antibiotics 101 135 7642 (7.6) 28 939 2 178 (7.5)
 Airway antibiotics 65 213 5208 (8.0) 18 971 1 430 (7.5)
 Urinary tract/skin antibiotics 44 525 3259 (7.3) 11 668 900 (7.7)
Antibiotic exposure in childhood‡:
 Any antibiotics 305 938 25 306 (8.3) 112 795 9 414 (8.4)
 Airway antibiotics 292 173 24 859 (8.5) 107 716 9 232 (8.6)
 Urinary tract/skin antibiotics 64 676 5922 (9.2) 23 721 2 132 (9.0)
Antibiotics assumed from hospital
diagnosis§
21 413 3438 (16.1) 7 885 1 246 (15.8)
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*ICD-10: respiratory distress of the newborn (P22), congenital pneumonia (P23), neonatal aspiration syndromes (P24),
interstitial emphysema and related conditions originating in perinatal period (P25), pulmonary haemorrhage originating in
perinatal period (P26), chronic respiratory disease originating in perinatal period (P27), and other respiratory conditions
originating in perinatal period (P28).
†At least one antibiotic prescription to mothers during estimated duration of pregnancy.
‡At least one antibiotic prescription/hospital diagnosis associated with antibiotics in childhood.
§ICD-10: appendicitis (K35), sepsis (A40-A41), meningitis (A87, G00-G03), pneumonia (J18), skin infection (L08),
cystitis (N30), and pyelonephritis (N10).
Table 2
 Maternal characteristics in full cohort and sibling cohort in analysis of association between fetal and
childhood exposure to antibiotics and development of asthma
Full cohort Sibling cohort
No of children No (%) with asthma No of children No (%) with asthma
Total No of children 493 785 29 753 (6.0) 180 894 11 260 (6.2)
Mode of delivery:
 Vaginal 366 662 20 712 (5.7) 136 452 7 870 (5.8)
 Instrumental 38 333 2235 (5.8) 12 746 814 (6.4)
 Elective caesarean section 37 934 2911 (7.7) 17 893 1 054 (7.7)
 Emergency caesarean section 50 569 3880 (7.7) 13 687 1 518 (8.5)
 Missing 287 15 (5.2) 116 4 (3.5)
Smoking during pregnancy:
 No 439 962 25 516 (5.8) 162 490 9 806 (6.0)
 Yes 32 743 2766 (8.5) 10 184 877 (8.6)
 Missing 21 080 1471 (7.0) 8 220 577 (7.0)
Age at delivery (years):
 <19 7746 462 (6.0) 1 972 149 (7.6)
 19-24 61 960 3954 (6.4) 23 118 1 660 (7.2)
 25-29 140 790 8873 (6.3) 56 079 3 727 (6.7)
 30-34 173 923 10 395 (6.0) 66 494 3 907 (5.9)
 ≥35 109 366 6069 (5.6) 33 231 1 817 (5.5)
Parity (at current delivery):
 1 216 643 11 869 (5.5) 65 781 4 287 (6.5)
 2 181 919 11 805 (6.5) 80 583 4 767 (5.9)
 3 66 979 4200 (6.3) 22 647 1 386 (6.1)
 ≥4 28 244 1879 (6.7) 11 883 820 (6.9)
Family situation:
 Mother and father cohabit 444 030 26 454 (6.0) 165 892 10 205 (6.2)
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 Mother lives alone, other 27 164 1761 (6.5) 6 279 452 (7.2)
 Missing 22 591 1538 (6.8) 8 723 603 (6.9)
Country of birth:
 Sweden 393 578 25 007 (6.4) 148 548 9 562 (6.4)
 Other Nordic countries 7561 448 (5.9) 2 649 174 (6.6)
 Other 92 646 4298 (4.6) 29 697 1 524 (5.1)
Parents’ highest level of education (years):
 0-9 24 141 1576 (6.5) 8 023 557 (6.9)
 10-12 180 539 12 239 (6.8) 62 781 4 305 (6.9)
 >12 286 922 15 874 (5.5) 109 666 6 386 (5.8)
 Missing 2183 64 (2.9) 424 12 (2.8)
Maternal asthma:
 No 453 278 24 733 (5.5) 162 887 9 113 (5.6)
 Yes 40 507 5020 (12.4) 18 007 2 147 (11.9)
Table 3
 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to exposure to antibiotics in fetal
life, overall and by trimester, in full cohort of children and for children with siblings
Groups of
antibiotics
All children* Children with siblings
Crude† HR
(95% CI)
Adjusted‡§ HR
(95% CI)
No of
cases¶
Crude HR
(95% CI)
No of
cases¶
Adjusted§ HR
(95% CI)
Any
Overall 1.36 (1.32 to
1.39) 1.28 (1.25 to 1.32) 2799
1.00 (0.94 to
1.08) 2523 0.99 (0.92 to 1.07)
Trimester:
 1 1.35 (1.30 to
1.40) 1.29 (1.23 to 1.34) 1 081
1.07 (0.95 to
1.20) 965 1.09 (0.97 to 1.23)
 2 1.39 (1.34 to
1.44) 1.30 (1.25 to 1.35) 1 312
0.99 (0.90 to
1.10) 1 171 0.97 (0.87 to 1.08)
 3 1.33 (1.28 to
1.39) 1.26 (1.21 to 1.31) 1 913
0.95 (0.85
to1.06) 1 078 0.95 (0.84 to 1.06)
Airway
Overall 1.41 (1.37 to
1.46) 1.31 (1.27 to 1.35) 1971
0.99 (0.91 to
1.07) 1773 0.98 (0.90 to 1.07)
Trimester:
 1 1.51 (1.43 to
1.58) 1.40 (1.33 to 1.47) 656
1.09 (0.94 to
1.26) 588 1.11 (0.95 to 1.30)
 2 1.45 (1.39 to
1.51) 1.33 (1.27 to 1.39) 863
0.97 (0.86 to
1.10) 768 0.97 (0.85 to 1.11)
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 3 1.33 (1.27 to
1.39) 1.24 (1.18 to 1.30) 817
0.95 (0.83 to
1.09) 738 0.96 (0.84 to 1.11)
Urinary tract/skin
Overall 1.25 (1.20 to
1.30) 1.23 (1.18 to 1.28) 1209
1.01 (0.91 to
1.12) 1087 0.98 (0.88 to 1.10)
Trimester:
 1 1.16 (1.09 to
1.23) 1.15 (1.08 to 1.22) 437
1.07 (0.90 to
1.28) 391 1.10 (0.91 to 1.33)
 2 1.30 (1.23 to
1.37) 1.26 (1.19 to 1.33) 544
0.99 (0.85 to
1.16) 485 0.93 (0.78 to 1.10)
 3 1.31 (1.24 to
1.39) 1.28 (1.21 to 1.36) 460
0.94 (0.79 to
1.12) 415 0.92 (0.76 to 1.10)
*Excludes children born to mothers with prescriptions for antibiotics without license in Sweden during study period (n=9).
†23 900 000 person years and 29 745 events. Individuals with reported event before date of entry (birth) were excluded
(n=8).
‡22 600 000 person years and 28 055 events.
§Adjusted for maternal smoking during pregnancy, parity, family situation (cohort and sibling analyses), and mother’s
country of birth, parental education, maternal asthma (cohort analyses), and age as analysis time scale. Individuals with
missing information on included variables excluded.
¶All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to
estimates in table therefore number of cases is number of families with siblings discordant for both antibiotic exposure and
asthma.
Table 4
 Hazard ratios (HR) and 95% confidence interval for asthma in relation to age at exposure to any antibiotics
in childhood in full cohort of children
Age
(years)
Crude Adjusted * Adjusted†
Person years
(1000) Events
HR (95%
CI)
Person years
(1000) Events
HR (95%
CI)
Person
years
(1000) Events
HR
(95%
CI)
0-0.5 245 4996 3.97 (3.66
to 4.30)
233 4715 3.71 (3.41
to 4.03)
233 4715 3.78
(3.48 to
4.10)
0.5-1 241 8753 2.74 (2.61
to 2.87)
229 8294 2.59 (2.47
to 2.72)
229 8294 2.61
(2.49 to
2.74)
1-1.5 224 6486 2.43 (2.31
to 2.55)
213 6133 2.31 (2.20
to 2.43)
213 6133 2.32
(2.20 to
2.44)
1.5-2 194 4595 2.17 (2.04 183 4337 2.06 (1.93 183 4337 2.06
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to 2.31) to 2.19) (1.93 to
2.20)
≥2 655 4915 1.90 (1.77
to 2.03)
612 4601 1.80 (1.68
to 1.93)
612 4601 1.81
(1.69 to
1.94)
*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal antibiotic exposure in fetal life, mother’s birth country, parental education, and
age as analysis time scale. Individuals with reported event before date of entry (birth) were excluded (n=312). Individuals
with missing information on included variables excluded.
†Additionally adjusted for antibiotic exposure defined from hospital diagnoses.
Table 5
 Hazard ratios (HR) and 95% confidence interval for asthma in relation to age at exposure to any antibiotics
in childhood in children with siblings
Age (years)
Crude Adjusted* Adjusted†
No of cases‡ HR (95% CI) No of cases‡ HR (95% CI) No of cases‡ HR (95% CI)
0-0.5 1109 1.89 (1.49 to 2.41) 993 2.11 (1.61 to 2.76) 830 2.23 (1.71 to 2.91)
0.5-1 1704 1.51 (1.34 to 1.71) 1541 1.46 (1.28 to 1.67) 1337 1.47 (1.29 to 1.68)
1-1.5 955 1.77 (1.53 to 2.04) 859 1.82 (1.55 to 2.13) 768 1.80 (1.53 to 2.11)
1.5-2 547 1.46 (1.18 to 1.80) 498 1.50 (1.19 to 1.89) 462 1.51 (1.20 to 1.91)
≥2 600 1.32 (0.99 to 1.76) 556 1.32 (0.97 to 1.79) 507 1.31 (0.96 to 1.78)
*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal antibiotic exposure in fetal life, age as analysis time scale, and parity included as
interaction term with age. Individuals with missing information on included variables excluded.
†Additionally adjusted for antibiotic exposure defined from hospital diagnoses.
‡All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to
estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and
asthma.
Table 6
 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to age at exposure to airway and
urinary tract/skin antibiotics in childhood in full cohort of children
Age (years)
Airway antibiotics* Urinary tract/skin antibiotics*
Crude HR (95% CI) Adjusted† HR (95% CI) Crude HR (95% CI) Adjusted† HR (95% CI)
0-0.5 4.46 (4.10 to 4.86) 4.12 (3.78 to 4.50) 1.64 (1.33 to 2.03) 1.54 (1.24 to 1.92)
0.5-1 2.83 (2.70 to 2.97) 2.65 (2.52 to 2.78) 1.60 (1.43 to 1.79) 1.54 (1.38 to 1.72)
1-1.5 2.49 (2.37 to 2.61) 2.34 (2.23 to 2.47) 1.41 (1.27 to 1.56) 1.37 (1.23 to 1.53)
1.5-2 2.20 (2.07 to 2.34) 2.07 (1.94 to 2.20) 1.22 (1.09 to 1.36) 1.19 (1.07 to 1.34)
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≥2 1.91 (1.79 to 2.04) 1.79 (1.68 to 1.92) 1.21 (1.11 to 1.32) 1.20 (1.10 to 1.31)
*Person time and number of events in cohort analyses of airway and urinary tract/skin antibiotics, same as for table 4 any
antibiotics. Individuals with reported event before date of entry (birth) were excluded (n=312).
†Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal exposure to antibiotics in fetal life, mother’s country of birth, parental education,
and age as analysis time scale. Individuals with missing information on included variables excluded.
Table 7
 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to age at exposure to airway and
urinary tract/skin antibiotics in childhood for children with siblings
Age
(years)
Airway antibiotics Urinary tract/skin antibiotics
Crude Adjusted* Crude Adjusted*
Cases† HR (95% CI) Cases† HR (95% CI) Cases† HR (95% CI) Cases†
HR (95%
CI)
0-0.5 1075 2.16 (1.68 to
2.79)
961 2.36 (1.78 to
3.13)
129 0.70 (0.41 to
1.20)
114 0.85 (0.47 to
1.55)
0.5-1 1655 1.56 (1.37 to
1.77)
1494 1.51 (1.31 to
1.73)
255 0.93 (0.71 to
1.21)
226 0.94 (0.70 to
1.25)
1-1.5 931 1.85 (1.59 to
2.14)
837 1.91 (1.62 to
2.24)
234 0.98 (0.73 to
1.30)
216 0.98 (0.72 to
1.33)
1.5-2 546 1.50 (1.21 to
1.86)
496 1.54 (1.22 to
1.95)
175 1.02 (0.71 to
1.45)
161 0.98 (0.66 to
1.44)
≥2 628 1.38 (1.04 to
1.84)
580 1.38 (1.02 to
1.86)
292 0.97 (0.67 to
1.41)
264 0.95 (0.63 to
1.42)
*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal exposure to antibiotics in fetal life, age as analysis time scale, and parity
included as interaction term with age. Individuals with missing information on included variables excluded.
†All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to
estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and
asthma.
Table 8
 Hazard ratios (HR) and 95% confidence intervals for asthma from age 2 in relation to exposure to any,
airway, and urinary tract/skin antibiotics in first year of life in full cohort of children
Crude* HR (95% CI) Adjusted†‡ HR (95% CI)
Any 1.18 (1.11 to 1.26) 1.23 (1.15 to 1.32)
Airway 1.19 (1.12 to 1.27) 1.24 (1.16 to 1.33)
Urinary tract/skin 1.25 (1.08 to 1.43) 1.24 (1.08 to 1.44)
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*655 137 person years and 4915 events.
†612 270 person years and 4601 events.
‡Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal exposure to antibiotics in fetal life, mother’s country of birth, parental education,
and age as analysis time scale. Individuals with missing information on included variables excluded.
Table 9
 Hazard ratios (HR) and 95% confidence intervals for asthma from age 2 in relation to exposure to any,
airway, and urinary tract/skin antibiotics in first year of life for children with siblings
Crude Adjusted*
Cases† HR (95% CI) Cases† HR (95% CI)
Any 568 0.93 (0.70 to 1.23) 523 0.90 (0.66 to 1.23)
Airway 550 0.98 (0.74 to 1.30) 505 1.01 (0.75 to 1.38)
Urinary tract/skin 120 0.99 (0.56 to 1.74) 107 0.63 (0.32 to 1.25)
*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at
delivery, parity, family situation, maternal exposure to antibiotics in fetal life, age as analysis time scale, and parity
included as interaction term with age. Individuals with missing information on included variables excluded.
†All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to
estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and
asthma.
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Fig 2 Adjusted hazard ratio and 95% confidence interval for asthma in relation to time (in years) since first exposure to
various antibiotics in childhood. Hazard ratio adjusted for attained age, sex, birth weight, gestational age, mode of delivery,
respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, mother’s country of birth, and parental
education. UTI=urinary tract infection
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